CD4 and neoplasm: Second, due to financial constraints tissue and blood correlatives were not collected, which did not allow characterization of ADXS11-001’s ability to activate the innate adaptive CD4-positive and CD8-positive T cells within the tumor, as well as look at an association between treatment responses for ‘responders’ and ‘non-responders’.